The 4 most recent market catalysts affecting $ICLR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Reiterates Buy on Icon, Raises Price Target to $209
Truist Securities analyst Jailendra Singh reaffirmed a 'Buy' rating for Icon (ICLR) and modestly increased the price target from $207 to $209. This action signals ongoing analyst c…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
ICON shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline signifies a strong corporate catalyst for ICON (ICLR), as better-than-expected financial results typically lead to increased investor confidence and upward price move…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 55
Icon Affirms FY2026 Adj EPS Guidance of $10.00-$11.00 vs $10.64 Est; Affirms FY2026 Sales Guidance of $7.850B-$8.150B vs $8.063B Est
Icon (ICLR) filed an 8-K to affirm its previously issued financial guidance for fiscal year 2026. Specifically, the company reiterated its adjusted EPS guidance of $10.00-$11.00 an…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
ICON shares are trading higher after the company announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle.
This collaboration is a major positive catalyst for ICON (ICLR), as it positions the company at the forefront of AI adoption in clinical research, potentially leading to significan…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.